Instrument NameSage Therapeutic ComInstrument Symbol(SAGE-Q)

Instrument ExchangeNASDAQ

A survey of North American equities heading in both directions

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.74%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.70%. US stock indexes Wednesday settled moderately lower, with the Dow Jones Industrials falling to...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.36%. US stock indexes today are moderately lower, with the Dow Jones Industrials falling to...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.62%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. US stock indexes today are moving lower as bond yields climb on concern the...

A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...

The pharmaceutical company's growth prospects have taken a big hit.

/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...

The company got bad news from the FDA and saw increased losses.

These companies aren't bargains at all.

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...

A regulatory setback weighed heavily on the drugmaker's shares Monday.

Stocks that traded heavily or had substantial price changes on Monday: Sovos Brands, Elanco Animal Health rise; Tyson Foods, Gogo fall

Sage's regulatory win wasn't enough to offset an even bigger regulatory loss.

A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in May:

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023.

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 2, 2023 at 8:00 a.m. ET to review first quarter 2023...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET.

VANCOUVER, BC / ACCESSWIRE / March 16, 2023 / Sage Potash Corp. (the "Company" or "Sage") is pleased to announce that its common shares will commence trading at market open on Monday, March 20, 2023 on the TSX Venture Exchange under the ticker...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss...